Affiliation:
1. School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
2. Sanofi Korea Co., Ltd., Seoul 06578, Republic of Korea
Abstract
In South Korea, the ready-to-use hexavalent vaccine (against diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and hepatitis B) is not listed despite its facility of no need to reconstitute. It, therefore, has the potential to augment the efficiency of prevention against the six infectious diseases, and it may reduce vaccine-related errors of reconstitution when compared with the currently used vaccination scheme of the pentavalent vaccine with the additional shots against hepatitis B. Given the assumed clinical equivalence between the two vaccination schemes, a cost-minimization analysis has been performed from a societal perspective including all the medical and non-medical direct and indirect costs when vaccinating one birth cohort. The results indicate that the ready-to-use hexavalent vaccine induces a cost reduction of KRW 47,155 (USD36.22) per infant or 12,026 million Korean Won ($9,236,417) in total for the whole birth cohort with 260,500 children. Using the ready-to-use hexavalent vaccine causes a lower infection rate, has fewer vaccination sessions, and may save much time as compared with the current vaccination scheme in place. The ready-to-use hexavalent vaccine may, therefore, benefit the National Immunization Program by reducing the total societal costs of vaccination while improving convenience of infants, parents, and medical care professionals.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference26 articles.
1. Kroger, A.B.L., and Hunter, P. (2022). General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP).
2. Combination vaccines;Skibinski;J. Glob. Infect. Dis.,2011
3. The use of combination vaccines has improved timeliness of vaccination in children;Kalies;Pediatr. Infect. Dis. J.,2006
4. Kinrix: A new combination DTaP-IPV vaccine for children aged 4–6 years;Weston;Expert Rev. Vaccines,2008
5. Safety of immunization injections in Africa: Not simply a problem of logistics;Dicko;Bull. World Health Organ.,2000
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献